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The papillomavirus E2 proteins regulate viral replication, gene transcription, and genome maintenance by
interacting with other viral and host proteins. From a yeast two-hybrid screen, we identified the cellular protein
Tax1BP1 as a novel binding partner of human papillomavirus type 18 (HPV18) E2. Tax1BP1 also interacts with
the HPV16 and bovine papillomavirus type 1 (BPV1) E2 proteins, with the C-terminal region of Tax1BP1
interacting with the N-terminal transactivation domain of BPV1 E2. Tax1BP1 complexes with p300 and acts
synergistically as a coactivator with p300 to enhance E2-dependent transcription. Using chromatin immuno-
precipitation assays, we show that Tax1BP1 and E2 localize to the long control region on the BPV1 genome.
Tax1BP1 was recently reported to bind ubiquitin and to function as an essential component of an A20
ubiquitin-editing complex. We demonstrate that Tax1BP1 plays a role in the regulation of the steady-state level
of E2 by preventing its proteasomal degradation. These studies provide new insights into the regulation of E2
functions.
The papillomavirus E2 protein is a key regulator of viral
DNA replication, gene expression, and genome maintenance.
The E2 proteins are structurally and functionally conserved
across different papillomaviruses and are composed of an
N-terminal transactivation domain (TAD) and a C-terminal
dimerization and DNA binding domain (DBD) separated by a
less conserved proline-rich hinge region (reviewed in reference
32). The N-terminal TAD is essential for E2 functions and
interacts with numerous viral and cellular proteins, including
the viral E1 protein, TFIIB, GPS2/AMF-1, MKlp2, CHlR1,
Brd4, Brahma, NAP-1, p300/CBP, and p/CAF (20, 23, 24, 29,
33, 36, 38, 44, 45). The E2 DBD binds to the E2-responsive
elements, specific palindromic sequences (ACCN6GGT) lo-
cated mainly in the long control region (LCR) of the viral
genome (1). Upon binding to the E2-responsive element, E2
activates gene transcription from viral early and late promot-
ers. Besides the 410-amino-acid (aa) transcriptional activator
E2, the open reading frame of the bovine papillomavirus type
1 (BPV1) E2 also encodes a transcriptional repressor, E2R (aa
162 to 410), which is expressed from the C-terminal part of the
E2 open reading frame and represses E2-dependent transcrip-
tion due to a lack of functional TAD (21).
Tax1-binding protein 1 (Tax1BP1) (also named TXBP151
and T6BP) was originally identified as a binding partner of the
human T-cell leukemia virus type 1 Tax oncoprotein (6, 28).
The N-terminal region (aa 1 to 150) of Tax1BP1 contains a
SKIP carboxyl homology (SKICH) domain. The central region
(aa 150 to 600) is predicted to form three coiled-coil domains
and is involved in self-dimerization. The C-terminal region (aa
601 to 789) encodes two zinc fingers. Tax1BP1 is highly con-
served across the species, with human Tax1BP1 sharing 79%
and 81% identity with rat and mouse orthologs, respectively. It
is a nuclear protein and is abundantly expressed in most human
tissues and established cell lines (4, 6).
Tax1BP1 is a negative regulator of NF-B signaling. It in-
teracts with TRAF6 in an interleukin 1-dependent manner and
reduces the polyubiquitination of RIP1 and TRAF6 signaling
intermediates by recruiting the ubiquitin-editing enzyme A20
(16, 28, 39). The second zinc finger at the C terminus of
Tax1BP1 contains a ubiquitin-binding domain. Mutations in
this region abolished ubiquitin binding and TRAF6 associa-
tion. Moreover, through its two zinc finger domains and the
associated “PPXY” motifs, Tax1BP1 recruits the E3 ligase Itch
to form a functional A20 ubiquitin-editing complex, which is
essential for the termination of NF-B signaling (40). Tax1BP1
knockout mice exhibit elevated NF-B activation in response
to tumor necrosis factor alpha and interleukin 1 stimulation. In
addition, Tax1BP1 also serves as a transcriptional coactivator
of glucocorticoid receptor by stimulating glucocorticoid re-
sponse element-dependent reporter through its N-terminal ac-
tivation domain (4).
To better understand the regulation of E2 functions, we
performed a yeast two-hybrid screen of a HeLa cDNA library
using human papillomavirus type 18 (HPV18) E2 as bait and
identified Tax1BP1 as a novel E2-interacting protein. Here, we
show that Tax1BP1 interacts with both HPV and BPV E2
proteins. Tax1BP1 functions synergistically as a coactivator
with p300 in E2-dependent transcription. In addition, Tax1BP1
interaction significantly extends the half-life of E2 proteins by
preventing their proteasomal degradation.
MATERIALS AND METHODS
Plasmids and antibodies. The full-length Tax1BP1 human cDNA construct
was purchased from ATCC (catalog no. 10436569; human 6055189). FLAG-
tagged full-length Tax1BP1 (aa 1 to 789), TXBP-Nter (aa 1 to 420), and TXBP-
Cter (aa 421 to 789) were cloned in frame into the p3XFLAG-CMV-7.1 vector
(Sigma) by PCR amplification using specific primers containing NotI and BamHI
restriction sites. The FLAG-tagged Tax1BP1 ubiquitin-binding domain mutants
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(UBZ1, UBZ2, and UBZ*) were generated by PCR (16). The BPV1 and HPV16
E2 expression plasmids have been previously described (3, 36). The hemagglu-
tinin (HA)-tagged HPV18 E2 expression plasmid was constructed by PCR am-
plification of the HPV18 E2 coding sequence from pSGE2-18 using specific
primers containing BamHI and EcoRI restriction sites and inserting it in frame
into a pcDNA-HA expression vector (43).
The following antibodies were used: mouse anti-FLAG (M2; Sigma), rabbit
anti-FLAG (F7425; Sigma), anti-c-Myc (9E10; Santa Cruz), anti-HA (12CA5
[34]), anti-EE (13), B201 (a mouse monoclonal antibody whose epitope maps
between aa 160 and 220 of BPV1 E2), B202 (a mouse monoclonal antibody
whose epitope maps between aa 285 and 325 of BPV1 E2), II-1 (rabbit anti-
BPV1 E2 antiserum), TVG261 (mouse anti-HPV16 E2 monoclonal antibody),
and anti--actin (Sigma). Goat anti-mouse– and goat anti-rabbit–horseradish
peroxidase were purchased from Jackson ImmunoResearch. The rabbit poly-
clonal TXBP151-C antibody was kindly provided by Kuan-Teh Jeang (6).
Yeast two-hybrid assay. The initial yeast two-hybrid screen was performed in
Saccharomyces cerevisiae strain DBY1 transformed with a HeLa cDNA library
fused to the herpesvirus VP16 activation domain, along with an E2-dependent
lacZ reporter, pBSY72, in which the URA3 gene was replaced by the HIS4 gene
(pBSY72-H4) (3). pRS314G-18E2 was constructed by inserting HPV18 E2 into
a yeast centromere vector, pRS314 (41). Yeast transformants were selected on
minimal medium containing X-Gal (5-bromo-4-chloro-3-indolyl--D-galactopy-
ranoside).
To confirm Tax1BP1 interaction with BPV1 E2, pYEplac112G, encoding
galactose-inducible BPV1 E2, and pGADT7, encoding Tax1BP1, were trans-
formed into DBY1 cells containing pBSY72. Transformants were selected on
galactose–X-Gal medium.
Cell culture and transient transfections. Human C33A cervical carcinoma
cells and mouse mammary tumor fibroblast (C127)-derived A3 cells (generously
provided by M. Botchan [25]), which stably maintain BPV1 genomes, were
cultured in Dulbecco’s modified Eagle’s medium (DMEM) (Invitrogen) with
10% fetal calf serum. The cells were washed and transfected in serum-free
DMEM using Lipofectamine 2000 (Invitrogen) and refed with DMEM with 10%
fetal calf serum.
Coimmunoprecipitation assays and Western blot analysis. Cells were lysed on
ice for 20 min in lysis buffer (50 mM Tris-HCl, pH 8.0, 100 mM NaCl, 20 mM
NaF, 50 mM KH2PO4, 1% Triton X-100, 10% glycerol, 2 mM dithiothreitol
[DTT], 1 mM phenylmethylsulfonyl fluoride [PMSF], and protease inhibitor
cocktail [Roche]). The lysates were cleared by centrifugation and mixed with
equal volumes of binding buffer (50 mM Tris-HCl, pH 8.0, 100 mM KCl, 0.1 mM
EDTA, 0.2% NP-40, 0.1% bovine serum albumin, 2.5% glycerol, 2 mM DTT, 1
mM PMSF, and protease inhibitor cocktail). Protein A/G-Sepharose beads and
the respective antibodies were added, incubated overnight at 4°C, and washed
with wash buffer (100 mM Tris-HCl, pH 8.0, 100 to 300 mM NaCl, 0.5% NP-40,
2 mM DTT, and 1 mM PMSF). Coimmunoprecipitated proteins were resolved
by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE),
transferred to polyvinylidene difluoride membranes (Millipore), and detected by
chemiluminescence (Pierce).
Chromatin immunoprecipitation (ChIP) assays. Forty-eight hours posttrans-
fection, cells were fixed with 1% formaldehyde at room temperature for 10 min.
The cells were rinsed with phosphate-buffered saline and lysed on ice for 10 min
in lysis buffer (1% SDS, 5 mM EDTA, 50 mM Tris-HCl, pH 8.0, and protease
inhibitor cocktail). The sonicated cell lysates were cleared by centrifugation,
diluted 10-fold in dilution buffer (1% Triton X-100, 2 mM EDTA, 150 mM NaCl,
20 mM Tris-HCl, pH 8.0), and incubated overnight at 4°C with the respective
antibodies and protein A/G-Sepharose beads (preblocked with 1% bovine serum
albumin and sheared salmon sperm DNA in Tris-EDTA buffer [GE Health-
care]). The beads were washed sequentially in low-salt buffer (0.1% SDS, 1%
Triton X-100, 2 mM EDTA, 20 mM Tris-HCl, pH 8.0, 150 mM NaCl), high-salt
buffer (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris-HCl, pH 8.0, 500
mM NaCl), LiCl buffer (0.25 M LiCl, 1% NP-40, 1% deoxycholate, 1 mM EDTA,
10 mM Tris-HCl, pH 8.0), and Tris-EDTA buffer. Protein-DNA complexes were
eluted from the beads at room temperature for 10 min in elution buffer (1% SDS,
0.1 M NaHCO3) and then reverse cross-linked overnight at 65°C. DNA was
recovered using a PCR purification kit (Qiagen) and was subjected to PCR
amplification of the BPV1 LCR using the following primers: BPV1LCRS (5-A
AAGTTTCCATTGCGTCTGG-3) and BPV1LCRAS (5-GCTTTTTATAGTT
AGCTGGCTATTTT-3).
Proteasome inhibition assays. Approximately 5  105 C33A cells were trans-
fected with 100 ng of expression constructs for wild-type BPV1 E2, the truncation
mutant E2TAD or E2R, and 1 g of FLAG-tagged full-length Tax1BP1 or 500
ng of TXBP-Nter and TXBP-Cter. Forty hours posttransfection, the proteasome
inhibitor MG132 dissolved in dimethyl sulfoxide (DMSO) was added to the cells
for 6 to 8 h at a final concentration of 10 M. The cells were lysed in lysis buffer
(2% SDS, 50 mM Tris-HCl, pH 6.8). The protein concentration was determined
using a bicinchoninic acid protein assay kit (Pierce).
Cycloheximide chase assays. Approximately 5  105 C33A cells were trans-
fected with 100 ng of pCG-E2b and 1 g of FLAG-tagged full-length Tax1BP1
or 500 ng of TXBP-Nter and TXBP-Cter. Forty hours posttransfection, the cells
were treated with cycloheximide at a final concentration of 50 g/ml and lysed
immediately and after 0.5, 1, 2, 4, and 8 h in lysis buffer (2% SDS, 50 mM
Tris-HCl, pH 6.8). The protein concentration was determined by a bicinchoninic
acid assay.
Reporter assays. Approximately 5  105 C33A cells were transfected using
Lipofectamine 2000 with 100 ng of the E2-dependent reporter plasmid pGL2-
4BS-Luc, which contains four E2 binding sites fused to the simian virus 40
minimal promoter. Other expression vectors included 10 ng of pCG-E2b, 500 ng
of the p300 expression construct pCMV-p300NHA, 200 ng of the adenovirus
E1A 12S protein expression construct pCMV-E1A12S (36), and 1 g of FLAG-
tagged full-length or truncated Tax1BP1 constructs. Luciferase activities were
measured at 24 h posttransfection with the luciferase assay system (Promega).
RNA extraction and RT-PCR. Total RNA was extracted using TRIzol reagent
(Invitrogen) and treated with RQ1 RNase-free DNase (Promega) to remove
transfected plasmid DNA. After phenol-chloroform extraction, 250 ng of RNA
was subjected to reverse transcription (RT)-PCR using ImProm-II reverse trans-
criptase (Promega). BPV1 E2 cDNA was amplified by PCR in 30 cycles using the
following primers: BS16&17sense (5-GGTGGTAGAGGTGGAGTTTGATG-
3) and BS16&17anti (5-AGTAGTAGAGCCCAGTTCCGTCAG-3). Glycer-
aldehyde-3-phosphate dehydrogenase (GAPDH) cDNA was amplified by PCR
in 25 cycles using the following primers: G3S (5-ACCACAGTCCATGCCATC
AC-3) and G3A (5-TCCACCACCCTGTTGCTGTA-3).
In vivo ubiquitination assays. C33A cells were transfected with expression
constructs for BPV1 E2 and FLAG-tagged full-length Tax1BP1 and HA-tagged
ubiquitin. Forty hours posttransfection, the proteasome inhibitor MG132 dis-
solved in DMSO was added to the cells for 6 to 8 h at a final concentration of 10
M. The cells were lysed in lysis buffer (50 mM Tris-HCl, pH 8.0, 150 mM NaCl)
with 0.5% SDS. The SDS was then diluted to 0.1% with lysis buffer. The lysates
were sonicated using a Sonic Dismembrator (Fisher Scientific), boiled for 2 min,
and cleared by centrifugation. Protein A/G-Sepharose beads and rabbit anti-E2
(II-1) antiserum or rabbit immunoglobulin G (IgG) were added, incubated
overnight at 4°C, and washed with lysis buffer. The coimmunoprecipitated pro-
teins were resolved by SDS-PAGE and detected by Western blotting.
siRNA knockdown. Tax1BP1-small interfering RNA 1 (siRNA-1) and Tax1BP1–
siRNA-2 sequences have been described by Iha et al. (16). Silencer Negative Control
no. 1 siRNA was purchased from Applied Biosystems (AM4635). Approximately
3  105 C33A cells were transfected using Lipofectamine 2000 with Tax1BP1-
siRNA-1 and -2 (75 nM each) or negative control siRNA (150 nM) for 24 h, followed
by a second siRNA transfection, along with 200 ng of pCG-E2b for 48 h prior to
RT-PCR and Western blot analyses as described above. Tax1BP1 cDNA was am-
plified by PCR in 25 cycles using the forward primer 5-CAAGGTTGGATGGAG
TACTGCTCGTGATTATTAC-3 and the reverse primer 5-GTAAGACCCTTT
TGTTCTGC-3.
RESULTS
Papillomavirus E2 interacts with Tax1BP1. TXBP151 is the
synonymic name of Tax1BP1, also known as TRAF6-binding
protein (T6BP). TXBP151 (GenBank accession no. U33821)
and T6BP (GenBank accession no. AF268075) are 747-aa
proteins that differ by only two residues (aa 233 and 234) (6,
28). A more recent cDNA sequence (GenBank accession
no. BC050358) encodes a larger 789-aa Tax1BP1. Sequence
alignment showed that 42 aa between aa 603 and 646 of
Tax1BP1 are absent in TXBP151, which might represent a
splicing variant. The full-length Tax1BP1 used throughout
this study refers to the 789-aa protein, and TXBP151 refers
to the 747-aa protein.
To identify novel cellular proteins that interact with HPV18
E2, a yeast two-hybrid screen of a HeLa cDNA library was
performed using full-length HPV18 E2 as bait. The cDNA
insert from one candidate was found to encode the C-terminal
222 aa of TXBP151. Since the BPV1 E2 protein shares a high
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degree of functional and structural homology with HPV E2
proteins, this interaction was analyzed in the yeast two-hybrid
assay using full-length Tax1BP1 and various BPV1 E2 mutants
(Table 1). The transactivation-defective E2 mutant F87L was
chosen to replace the wild-type full-length E2 as bait to avoid
the general transcriptional-activation property of the wild-type
E2. The C-terminal aa 541 to 886 of MKlp2, which bind BPV1
E2, were used as a positive control (46). BPV1 E2 F87L inter-
acted with full-length Tax1BP1, but the deletion mutants E2
55-410 and E2 162-410 did not.
To confirm this interaction in mammalian cells, we first
examined the interaction of HPV E2 with Tax1BP1 in coim-
munoprecipitation assays. Human C33A cervical carcinoma
cells were transfected with expression vectors for full-length
HPV16 E2 or HA-HPV18 E2 and FLAG-Tax1BP1. HPV16
and HPV18 E2 proteins were immunoprecipitated from the
FLAG-Tax1BP1-transfected extract only using anti-FLAG M2
antibody, but not the anti-EE control antibody. Neither
HPV16 nor HPV18 E2 was immunoprecipitated from the ex-
tracts that did not include FLAG-Tax1BP1 (Fig. 1A and B).
We also tested complexes of HPV16 E2 with endogenous
Tax1BP1. HPV16 E2 was expressed in C33A cells and lysates
reacted with an anti-Tax1BP1 antibody (TXBP151-C), fol-
lowed by immunoblotting for HPV16 E2. This experiment
revealed that HPV16 E2 coprecipitated with endogenous
Tax1BP1 (Fig. 1C).
Next, we examined the interaction of BPV1 E2 with
Tax1BP1. C33A cells were transfected with expression vectors
for FLAG-Tax1BP1, full-length BPV1 E2, or the truncation
mutant E2TAD (aa 1 to 215) or E2R (aa 162 to 410), which
encode the BPV1 E2 TAD and DBD, respectively (Fig. 2A).
FLAG-Tax1BP1 coprecipitated with full-length E2 and
E2TAD, but not with E2R (Fig. 2B). Reciprocal coimmuno-
precipitations were also performed. Consistently, both full-
length E2 and E2TAD coprecipitated with FLAG-Tax1BP1
(Fig. 2C). These data demonstrated that Tax1BP1 interacts
with BPV1 E2 and that this association requires the N-terminal
TAD of BPV1 E2.
When coexpressed with transactivation-competent E2, the
expression level of Tax1BP1 is markedly increased due to the
general transcriptional activation of BPV1 E2 (Fig. 2B, top,
Tax1BP1 input) (15). The lack of coimmunoprecipitation of
E2R with Tax1BP1 could be due to the low expression level
of Tax1BP1. In addition, since the E2 TAD interacts with
Tax1BP1, it is possible that the transactivation function of E2
might be required for Tax1BP1 association. To address these
issues, Tax1BP1 was transfected into C33A cells with the trans-
activation-defective E2 mutant E39G or E2R. When similar
levels of Tax1BP1 were coexpressed with E2 E39G, E2R, or
control vector, only E2 E39G coprecipitated with Tax1BP1
(Fig. 2D). E2R failed to coprecipitate with Tax1BP1, even
though the level of E2R protein was markedly greater than
that of E2 E39G. This result supports the conclusion that E2
interaction with Tax1BP1 requires its N-terminal TAD and
that the overlapping region between E2TAD and E2R (aa 162
to 215) is not sufficient for Tax1BP1 association. Furthermore,
the transactivation property of E2 is not required for Tax1BP1
association.
The initial yeast two-hybrid screen identified the C-termi-
nal 222 aa of TXBP151 as the region that interacts with
HPV18 E2, so this region was likely to interact with BPV E2.
Tax1BP1 is predicted to fold into coiled-coil structures in its
central portion. The N-terminal 1 to 420 residues encompass
the first two coiled-coil structures, which contain an activa-
tion domain and a self-association domain. The C-terminal
421 to 789 residues encompass the third coiled-coil structure
and two zinc finger domains (4, 28). Based on this struc-
tural prediction, N-terminal (TXBP-Nter) and C-terminal
(TXBP-Cter) truncation protein expression constructs were
made (Fig. 2A). C33A cells were transfected with full-length
BPV1 E2 and FLAG-tagged full-length Tax1BP1, TXBP-
Nter, or TXBP-Cter. As expected, E2 coimmunoprecipi-
tated with full-length Tax1BP1 and TXBP-Cter, but not with
TXBP-Nter (Fig. 2E).
Tax1BP1 synergizes with p300 to enhance E2-dependent tran-
scription. Cellular proteins, such as Gps2/AMF-1, Brd4,
TFIIB, NAP-1, Brahma, CBP/p300, and p/CAF, were reported
to interact with E2 and to enhance E2-dependent transcrip-
tion. To determine the biological function of Tax1BP1 in E2-
FIG. 1. Tax1BP1 interacts with HPV16 and HPV18 E2 proteins. (A
and B) C33A cells were transfected with expression vectors for FLAG-
Tax1BP1 (TXBP) or control vector, along with either HA-tagged
HPV18 E2 (A) or HPV16 E2 (B) expression plasmids. Cell extracts
were immunoprecipitated (IP) with anti-FLAG (M2) or anti-EE con-
trol antibodies and immunoblotted (IB) with antibodies against HA
(12CA5) (A) or HPV16 E2 (TVG261) (B). (C) Coimmunoprecipita-
tion of endogenous Tax1BP1 with HPV16 E2. C33A cell extracts
expressing HPV16 E2 were immunoprecipitated with an anti-Tax1BP1
antibody (TXBP151-C) or rabbit IgG and immunoblotted for HPV16
E2 (TVG261).
TABLE 1. Yeast two-hybrid assay results using full-length Tax1BP1
and various BPV1 E2 mutants
pYEplac112G pGADT7 insert X-Gal staina
E2 F87L Empty vector 
E2 F87L MKlp2 541–886 
E2 F87L Tax1BP1 FLb 
E2 55–410 Tax1BP1 FL 
E2 162–410 Tax1BP1 FL 
a , negative; , positive; , strongly positive.
b FL, full length.
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dependent transcription, C33A cells were transfected with
an E2-dependent luciferase reporter and vectors expressing
BPV1 E2, HA-p300, or FLAG-Tax1BP1. The E2 reporter
exhibited minimal basal activity, which was unaffected by the
overexpression of p300 or Tax1BP1. E2 strongly activated
the reporter 20-fold. Coexpression of p300 increased E2
activity by 20%. Coexpression of Tax1BP1 increased E2
activity by 80%. When coexpressed with p300, Tax1BP1
synergistically increased E2 activity 1.7-fold (Fig. 3A).
E2-dependent transcription requires p300 and can be in-
hibited by the adenovirus E1A 12S protein (19, 33, 36). In
agreement with previous studies, E1A inhibited the tran-
scriptional activity of E2 regardless of Tax1BP1 expression
(Fig. 3B). An E1A deletion mutant [E1A Del (2-36)], which
is defective in p300/CBP binding, failed to inhibit E2 trans-
activation (data not shown). Tax1BP1 enhanced p300-de-
pendent E2 transcriptional activity in a dose-dependent
manner (Fig. 3C). Neither TXBP-Nter nor TXBP-Cter en-
hanced E2 activity significantly (Fig. 3D). These results sug-
gest that Tax1BP1 cooperates with p300 in E2-dependent
transcription.
Based on these observations, we sought to test whether
Tax1BP1 and p300 form complexes in vivo. C33A cells were
transfected with expression vectors for FLAG-Tax1BP1 and
HA-tagged p300 or a Renilla luciferase (HA-RLuc) control.
p300 coprecipitated Tax1BP1, but HA-RLuc did not (Fig.
4). This demonstrates that Tax1BP1 and p300 form com-
plexes independent of BPV1 E2.
FIG. 2. Tax1BP1 interacts with BPV1 E2. (A) Schematic diagrams of BPV1 E2 and Tax1BP1 constructs. Y2H, matched region in the initial
yeast two-hybrid screen; WT, wild type. (B and C) C33A cells were transfected with expression vectors for FLAG-Tax1BP1 and the specified BPV1
E2 constructs. Reciprocal coimmunoprecipitations were performed by either immunoprecipitating (IP) BPV1 E2 (B201) and immunoblotting (IB)
for FLAG-Tax1BP1 (M2) (B) or immunoprecipitating FLAG-TXBP (M2) and immunoblotting for E2 (II-1) (C). (D) C33A cells were transfected
with expression vectors for FLAG-Tax1BP1 and E2 E39G, E2R, or control vector. Cell extracts were immunoprecipitated with anti-FLAG M2
antibody and immunoblotted for E2 (II-1). (E) C33A cells were transfected with expression vectors for BPV1 E2 and FLAG-tagged full-length
Tax1BP1 (TXBP FL) or the truncation mutant TXBP-Nter or TXBP-Cter. Cell extracts were immunoprecipitated with anti-FLAG M2 antibody
and immunoblotted for E2 (II-1).
VOL. 83, 2009 Tax1BP1 INTERACTS WITH PAPILLOMAVIRUS E2 PROTEIN 2277
 at UNIV O
F M
ASS M
ED SCH on Novem






Tax1BP1 and E2 are present at the BPV1 LCR. E2 regulates
viral gene expression by binding to E2 binding sites in the viral
LCR and forming complexes with components of the basic tran-
scriptional machinery and transcription coactivators. Given that
Tax1BP1 interacts with BPV1 E2 and enhances E2-dependent
transcription, it is possible that Tax1BP1 is present, along with E2,
at the LCR. C33A cells were transfected with expression vectors
for BPV1 E2 and FLAG-Tax1BP1, as well as a BPV1 genome-
containing plasmid. ChIP assays were performed using mouse
anti-E2 (B201 and B202), anti-FLAG (M2), or control antibodies,
followed by PCR amplification of the BPV1 LCR. Antibodies
against E2 and FLAG-Tax1BP1 precipitated the viral LCR, but
the control antibodies did not (Fig. 5A). Similar results were
obtained using a set of rabbit antibodies against E2 (II-1) and
FLAG-Tax1BP1 (F7425 [Sigma] and TXBP151-C). To test
whether endogenous Tax1BP1 is present at the BPV1 LCR, ChIP
assays were performed on the A3 cell line harboring episomal BPV1
genomes. Antibodies against BPV1 E2 and endogenous Tax1BP1
precipitated the viral LCR (Fig. 5B). These results are consistent
with participation of Tax1BP1 in E2-dependent transcription.
Tax1BP1 stabilizes E2 by preventing its proteasome-medi-
ated degradation. HPV18 E2 and BPV1 E2 are degraded by
the ubiquitin-proteasome pathway (2, 37). We noticed in our
experiments that transient expression of Tax1BP1 increased
the BPV1 E2 protein level in a dose-dependent manner (Fig.
6A). Two possible explanations could account for this obser-
vation. First, Tax1BP1 may increase E2 transcription due to its
coactivator function. Secondly, Tax1BP could increase E2 pro-
tein stability. To examine the first possibility, E2 transcripts
from FLAG-Tax1BP1- and BPV1 E2-transfected cells were
amplified by semiquantitative RT-PCR at 24 and 48 h post-FIG. 3. Tax1BP1 and p300 synergistically enhance E2-dependent
transcription. The E2-dependent luciferase reporter was cotransfected
into C33A cells with various expression plasmids. Luciferase activities
were measured 24 h posttransfection and normalized against reporter
alone. Each sample was analyzed in triplicate (the error bars indicate
standard deviations). (A) Tax1BP1 and p300 synergistically enhance E2-
dependent transcription. Expression vectors for BPV1 E2, HA-p300, and
FLAG-Tax1BP1 alone or in combination were transfected as indicated.
(B) The coactivator function of Tax1BP1 is p300 dependent. Expression
vectors for BPV1 E2, FLAG-Tax1BP1, and adenovirus E1A 12S protein
were transfected as indicated. (C) Tax1BP1 enhances E2 transcriptional
activity in a dose-dependent manner. Expression vectors for BPV1 E2,
HA-p300, and increasing amounts of FLAG-Tax1BP1 (125 ng, 500 ng,
and 1 g) were transfected. (D) Full-length Tax1BP1 is required for its
coactivator function. Expression vectors for BPV1 E2 and FLAG-tagged
full-length Tax1BP1 or the truncation constructs TXBP-Nter and TXBP-
Cter were transfected.
FIG. 4. Tax1BP1 interacts with p300 in vivo. C33A cells were trans-
fected with expression vectors for FLAG-Tax1BP1 and HA-p300 or
HA-luciferase control (HA-RLuc). Cell extracts were immunoprecipi-
tated (IP) with anti-HA (12CA5) or anti-EE control antibodies and
immunoblotted (IB) for FLAG-Tax1BP1 (M2).
FIG. 5. E2 and Tax1BP1 are present at the BPV1 LCR. (A) A
BPV1 genome-containing plasmid was cotransfected into C33A cells
with expression vectors for BPV1 E2 and FLAG-Tax1BP1. Cell ex-
tracts were immunoprecipitated (IP) with mouse or rabbit antibodies
(Ab) against FLAG, E2, or Tax1BP1 or control antibodies. The LCR
of the BPV1 genome was amplified by PCR. (B) BPV1 genome-
containing A3 cell extracts were immunoprecipitated with anti-E2
(II-1) or anti-Tax1BP1 (TXBP151-C) antibodies or rabbit IgG. The
LCR of the BPV1 genome was amplified by PCR.
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transfection. The expression levels of transiently expressed
proteins were monitored by Western blotting. Compared to
control vector-transfected cells, Tax1BP1 slightly increased the
E2 protein level after 24 h (Fig. 6B, lane 1 versus lane 3). By
48 h posttransfection, the E2 level in Tax1BP1-transfected cells
was significantly higher than that in control vector-transfected
cells (Fig. 6B, lane 2 versus lane 4). However Tax1BP1 did not
alter the level of E2 transcripts at either time point, suggesting
that the accumulation of steady-state E2 protein in the pres-
ence of overexpressed Tax1BP1 is not likely a transcriptional
effect on cytomegalovirus promoter-driven E2 expression, but
rather, is caused by increased E2 stability (Fig. 6C).
FIG. 6. Tax1BP1 stabilizes E2 by preventing its proteasomal degradation. (A) Tax1BP1 increases the level of BPV1 E2 protein in a dose-dependent
manner. C33A cells were transfected with expression vectors for BPV1 E2 and increasing amounts of FLAG-Tax1BP1. Cell extracts were resolved on
SDS-PAGE and immunoblotted (IB) for FLAG-Tax1BP1 (M2), E2 (B201), or -actin. (B and C) C33A cells were transfected with expression vectors
for BPV1 E2 and FLAG-Tax1BP1 or control vector. (B) At 24 and 48 h posttransfection, cell extracts were resolved on SDS-PAGE and immunoblotted
for FLAG-Tax1BP1 (M2), E2 (B201), c-Myc (9E10), or -actin. (C) At 24 and 48 h posttransfection, total RNA was extracted using TRIzol reagent.
RNase-free DNase digestion of the isolated RNA was performed to remove the contamination of E2 plasmid DNA. E2 and GAPDH mRNAs were
amplified by semiquantitative RT-PCR. PCR using increasing amounts of E2 plasmid DNA as templates were also performed as a control. (D) Tax1BP1
prevents proteasomal degradation of BPV1 E2. C33A cells were transfected with expression vectors for BPV1 E2 and FLAG-Tax1BP1 or control vector.
At 40 h posttransfection, the cells were treated with 10 M MG132 or DMSO (mock) for 8 h. Cell extracts were resolved on SDS-PAGE and
immunoblotted for FLAG-Tax1BP1 (M2), E2 (B201), or -actin. (E) Tax1BP1 extends the half-life of BPV1 E2. C33A cells were transfected as described
for panel D. At 40 h posttransfection, the cells were treated with cycloheximide (50 g/ml) for up to 8 h. Cell extracts were resolved on SDS-PAGE and
immunoblotted for FLAG-Tax1BP1 (M2), E2 (B201), or -actin. (F) Graphical presentation of data presented in panel E. The level of E2 was
quantitated and normalized using -actin. (G) siRNA knockdown of endogenous Tax1BP1 reduces BPV1 E2 stability. C33A cells were transfected with
control or Tax1BP1 siRNA and expression vectors for BPV1 E2. Total RNA was extracted. Tax1BP1 and GAPDH mRNAs were amplified by RT-PCR.
Duplicated cell extracts were resolved on SDS-PAGE and immunoblotted for endogenous Tax1BP1 (TXBP151-C), E2 (B201), or -actin.
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Recent studies have shown that Tax1BP1 is an essential
subunit of the A20 ubiquitin-editing enzyme complex (40).
Tax1BP1 reduces polyubiquitination of RIP1 and TRAF6 by
recruiting the ubiquitin-editing enzyme A20 to these molecules
(6, 16, 39). To examine whether Tax1BP1 nonspecifically sta-
bilizes any ubiquitinated protein, the same cell lysates were
probed for c-Myc, which is degraded by the ubiquitin-pro-
teasome pathway (9). Overexpression of Tax1BP1 did not
change the levels of endogenous c-Myc at 24 and 48 h
posttransfection (Fig. 6B). Based on these findings, we hy-
pothesized that Tax1BP1 specifically prevents E2 degradation
by the ubiquitin-proteasome pathway. To test this hypothesis,
C33A cells were transfected with expression vectors for BPV1
E2 or FLAG-Tax1BP1 or with control vector for 40 h and then
treated with the proteasome inhibitor MG132 or DMSO
(mock treatment) for 8 h. The levels of E2 and Tax1BP1 were
examined by Western blotting. MG132 treatment greatly in-
creased the E2 protein level in vector-transfected cells, which
was similar to that in Tax1BP1-transfected cells (Fig. 6D, lane
1 versus lane 3 and lane 3 versus lane 4). MG132 treatment did
not significantly further increase the E2 protein level in
Tax1BP1-transfected cells (Fig. 6D, lane 2 versus lane 4).
These results indicate similar rates of E2 protein synthesis in
vector- and Tax1BP1-transfected cells. They also suggest that
the elevated E2 protein level caused by Tax1BP1 overexpres-
sion is primarily due to the inhibition of E2 proteasomal deg-
radation by Tax1BP1 (Fig. 6D, lane 2 versus lane 3).
To confirm that the increase in the E2 protein level was
indeed caused by changes to E2 stability, we performed cyclo-
heximide chase experiments using C33A cells transfected with
BPV1 E2 in the presence and absence of overexpressed
Tax1BP1. Forty hours posttransfection, cells were treated with
cycloheximide and lysed at different time points up to 8 h. In
control vector-transfected cell extracts, E2 protein degraded
with a half-life of 1.5 h, while overexpression of Tax1BP1
greatly extended its half-life to more than 8 h (Fig. 6E and F).
To determine the role of endogenous Tax1BP1 in E2 stabili-
zation, siRNA knockdown of endogenous Tax1BP1 was per-
formed in C33A cells. siRNA effectively reduced the level of
endogenous Tax1BP1 as determined by the level of Tax1BP1
transcript and protein (Fig. 6G). The level of E2 protein was
dramatically reduced as a result of siRNA knockdown, which is
consistent with the overexpression data and demonstrated the
role of Tax1BP1 in E2 stabilization.
To determine the region on Tax1BP1 that is responsible for
E2 stabilization, increasing amounts of the Tax1BP1 trunca-
tion mutants TXBP-Nter and TXBP-Cter and BPV1 E2 were
transfected into C33A cells. The level of E2 protein was mon-
itored by Western blotting. TXBP-Cter increased the E2 pro-
tein level in a dose-dependent manner, but TXBP-Nter did not
(Fig. 7A). MG132 treatment of vector-, TXBP-Nter-, and
TXBP-Cter-transfected cells caused E2 to accumulate to sim-
ilar levels (Fig. 7B). Cycloheximide chase experiments revealed
that the half-lives of E2 in vector- and TXBP-Nter-transfected
cells were approximately 1 h (similar to that shown in Fig. 6E)
but were significantly extended in TXBP-Cter-transfected cells
(Fig. 7C and D).
HPV18 E2 is degraded by the ubiquitin-proteasome path-
way through its TAD (2). The TAD of HPV18 E2 is more
efficiently ubiquitinated than the hinge/DBD. Since BPV1
E2TAD, but not E2R, interacts with Tax1BP1, we predicted
that only E2TAD would be stabilized by Tax1BP1. As ex-
pected, both full-length Tax1BP1 and TXBP-Cter stabilized
E2TAD, but not E2R (Fig. 8A and B). Similarly, full-length
Tax1BP1 also stabilized HPV16 E2 (data not shown).
E2 stabilization by Tax1BP1 is independent of Tax1BP1
ubiquitin binding. The C terminus of Tax1BP1 was recently
shown to harbor a ubiquitin-binding domain in the second zinc
finger (the UBZ2 domain) (16). The UBZ2 domain Tax1BP1
mutants were defective in ubiquitin binding and failed to
coimmunoprecipitate TRAF6, implying that Tax1BP1 might
interact with ubiquitinated TRAF6. To examine whether
Tax1BP1 interacts with ubiquitinated E2, Tax1BP1 UBZ
domain mutants were tested for E2 interaction and stabili-
zation. The two conserved Phe residues were mutated to Ala
in each of the two C-terminal zinc fingers (UBZ1, F737A;
UBZ2, F764A). Two cysteine residues in the UBZ2 domain
were also mutated (UBZ*, C757/760A). Both Tax1BP1 UBZ2
and UBZ* were defective in ubiquitin binding, whereas UBZ1
was not. BPV1 E2 coprecipitated with all UBZ domain mu-
tants, as well as wild-type Tax1BP1 and TXBP-Cter, but not
with TXBP-Nter (Fig. 9A). These UBZ mutants also stabilized
E2 significantly (Fig. 9B). Therefore, stabilization and binding
of E2 by Tax1BP1 does not require binding to ubiquitin. To
further determine whether Tax1BP1 affects the ubiquitination
status of E2, an in vivo ubiquitination assay was performed in
Tax1BP1- and HA-ubiquitin-coexpressed cell lysates. Surpris-
ingly, Tax1BP1 increased not only the level of nonubiquiti-
nated E2, but also the level of polyubiquitinated E2 species
(Fig. 9C). When the proteasomal function was inhibited by
MG132, nonubiquitinated and polyubiquitinated E2 species
accumulated to similar levels regardless of Tax1BP1 overex-
pression.
DISCUSSION
The identification and characterization of papillomavirus
E2-interacting proteins has provided valuable information for
our understanding of E2 functions. Here, we reported that
Tax1BP1 interacts with BPV and HPV E2 proteins in yeast and
mammalian cells, complexes with p300, and acts synergistically
with p300 to enhance E2-dependent transcription. In addition,
Tax1BP1 stabilizes E2 by preventing its proteasomal degrada-
tion. Since HPV and BPV E2 proteins have relatively short
half-lives, interaction with Tax1BP1 may illustrate another
mechanism to regulate their activities.
The E2 proteins are relatively well conserved in both the
N-terminal TAD and the C-terminal DBD among different
papillomaviruses (8, 31). While we used HPV18 E2 as bait in
a yeast two-hybrid screen, we also showed that Tax1BP1 inter-
acts with HPV16 and BPV1 E2 proteins. The interaction is
mediated through the N-terminal TAD of BPV1 E2 and the
C-terminal region of Tax1BP1. Even though these proteins
efficiently coimmunoprecipitated in vivo, we were unable to
detect direct binding between the glutathione S-transferase
fusion E2 and in vitro-translated Tax1BP1, possibly due to a
lack of required posttranslational modifications of the E2 pro-
tein produced in bacteria or other factors that facilitate their
association in vivo.
The papillomavirus E2 proteins are degraded by the ubiq-
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uitin-proteasome pathway. We demonstrated that full-length
Tax1BP1 and TXBP-Cter stabilize both full-length BPV1 E2
and E2TAD by preventing their degradation. Tax1BP1 did not
increase the E2R protein level, nor did Tax1BP1 stabilize c-
Myc, which has a short half-life and is also degraded through
the ubiquitin-proteasome pathway. These results suggest that
Tax1BP1 does not stabilize E2 as a result of interfering with
the proteasomal degradation of any ubiquitinated protein but
rather plays a specific role in regulating E2 stability. We also
observed that E2R is expressed at a much higher level than
full-length E2 or E2TAD, which is consistent with a previous
report that N-terminally truncated HPV18 E2 is more stable
than full-length E2 and the N-terminal TAD of HPV18 E2 is
highly ubiquitinated compared to the hinge/DBD (2). Alto-
gether, these findings suggest that the ubiquitination of the
N-terminal TAD of BPV1 E2 targets the protein for protea-
somal degradation.
Tax1BP1 is known to serve as an assembly platform for
protein deubiquitination. As reported, Tax1BP1 binds ubiq-
uitinated TRAF6 and recruits A20 to reduce TRAF6 ubiq-
uitination (16). However, our data do not support the hy-
pothesis that Tax1BP1 might utilize a similar mechanism to
stabilize E2 by preventing its ubiquitination. First, both
ubiquitin-binding-defective Tax1BP1 mutants (UBZ2 and
UBZ*) coimmunoprecipitate and stabilize BPV1 E2, indi-
cating that the association of Tax1BP1 with E2 is not me-
diated by ubiquitin (Fig. 9). Secondly, Tax1BP1 expression
did not cause a decrease in polyubiquitinated E2 accompanied by
an increase in nonubiquitinated E2 in the in vivo ubiquitination
assay. However, since proteasome functions are regulated by op-
posing deubiquitinating activities and ubiquitin ligase activities in
a dynamic balance (5), we cannot rule out the possibility that the
increased nonubiquitinated E2 species favor the ubiquitin ligase
activities until equilibrium is reached.
FIG. 7. The C-terminal region of Tax1BP1 stabilizes E2. (A) TXBP-Cter increases the level of BPV1 E2 protein in a dose-dependent manner. C33A cells
were transfected with expression vectors for BPV1 E2 and increasing amounts of the FLAG-tagged Tax1BP1 truncation construct TXBP-Nter or TXBP-Cter.
Cell extracts were resolved on SDS-PAGE and immunoblotted (IB) for FLAG-Tax1BP1 (M2), E2 (B201), or -actin. (B) TXBP-Cter prevents proteasomal
degradation of BPV1 E2 protein. C33A cells were transfected with expression vectors for BPV1 E2 and FLAG-tagged TXBP-Nter, TXBP-Cter, or control
vector. At 40 h posttransfection, the cells were treated with 10M MG132 or DMSO (mock) for 6 h and analyzed by Western blotting as described for Fig. 6D.
(C) TXBP-Cter extends the half-life of BPV1 E2 protein. C33A cells were transfected with expression vectors for BPV1 E2 and FLAG-tagged TXBP-Nter,
TXBP-Cter, or control vector. At 40 h posttransfection, cycloheximide chase experiments were performed and analyzed as described for Fig. 6E. (D) Graphical
presentation of data presented in panel C. The levels of E2 were quantitated and normalized using -actin.
FIG. 8. Tax1BP1 stabilizes the N-terminal TAD of BPV1 E2. C33A
cells were transfected with expression vectors for E2TAD (A) or E2R
(B) and FLAG-tagged full-length Tax1BP1, the truncation constructs
TXBP-Nter and TXBP-Cter, or control vector. At 40 h posttransfec-
tion, the cells were treated with 10 M MG132 or DMSO (mock) for
6 h and analyzed by Western blotting (IB) as described for Fig. 6D.
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The histone acetyltransferases CBP/p300 and p/CAF are
multifunctional regulators in the cells of higher eukaryotes. As
transcription coactivators, they promote gene transcription by
bridging between DNA-bound transcription factors and the
RNA polymerase II holoenzymes and by acetylating histones
and other transcription factors. CBP/p300 and p/CAF bind
papillomavirus E2 and activate E2-dependent transcription
(19, 23, 24, 33). We found that Tax1BP1 interacts with p300
and that the coactivator function of Tax1BP1 is p300 depen-
dent. Therefore, Tax1BP1 may be present in complexes with
E2 and p300 and enhance E2-dependent transcription.
ChIP assays showed that both Tax1BP1 and E2 precipitated
the BPV1 LCR. There are 12 E2 binding sites in the LCR (27).
We were unable to effectively sonicate viral minichromosomes
into smaller LCR-containing DNA fragments to distinguish
whether Tax1BP1 preferentially associated with E2 at a spe-
cific site. We also cannot rule out the possibility that Tax1BP1
may be tethered by E2 to E2 binding sites outside the LCR.
Since most of the high-affinity E2 binding sites are located
within the LCR, it is reasonable to expect that most
Tax1BP1-E2 complexes bind to these high-affinity sites. This
model is also consistent with the coactivator function of
Tax1BP1 in E2-dependent transcription.
In addition, CBP/p300 and p/CAF may exert their coactiva-
tor functions indirectly by regulating the turnover of transcrip-
tion factors. p300 and p/CAF were shown to stabilize Smad7,
SREBP, and E2F by acetylation (7, 10, 30, 42). p300 also
stabilizes MDM2 and ATF4 independently of its acetylase
activity, possibly by sequestration of MDM2 and ATF4 into
nuclear-body-like structures, thereby protecting these mole-
cules from proteasomal degradation (22, 47). The pleiotropic
functions of these histone acetyltransferases are illustrated by
the effects of p300 on p53 stability. p53 was the first nonhistone
protein reported to be acetylated by CBP/p300 (14, 18).
Acetylation of p53 inhibits its ubiquitination by Mdm2 (26).
Acetylated p53 is found in promyelocytic leukemia bodies with
CBP in Ras-overexpressing cells (35). In contrast, p300 partic-
ipates in MDM2-mediated p53 degradation (12). Recent data
also show that p300 possesses E4 ubiquitin ligase activity,
which promotes the polyubiquitination of p53 for proteasomal
degradation (11). Since the same lysine residues can be acety-
lated or ubiquitinated, what controls the switch between acet-
ylation and ubiquitination by p300 remains undetermined (17).
Interestingly Tax1BP1 also localizes in the intranuclear speck-
les that partially overlap with promyelocytic leukemia bodies
(4). By analogy, Tax1BP1 may bridge p300 and E2 and seques-
ter E2 into a nuclear compartment that is not accessible to
proteasomal degradation. Studies are under way to determine
whether Tax1BP1 regulates the subcellular localization of E2
and the potential involvement of p300 in Tax1BP1-mediated
E2 stabilization.
The stabilization of E2 by Tax1BP1 raised the question of
FIG. 9. E2 stabilization by Tax1BP1 is independent of Tax1BP1 ubiquitin binding. (A) Ubiquitin-binding-defective Tax1BP1 mutants interact
with BPV1 E2. C33A cells were transfected with expression vectors for BPV1 E2 and FLAG-tagged full-length wild-type Tax1BP1 (WT); the
ubiquitin-binding-defective mutants UBZ1, UBZ2, and UBZ*; or the truncation mutant TXBP-Nter or TXBP-Cter. To ensure equal levels of E2
inputs, the cells were treated with 10 M MG132 for 6 h. Cell extracts were immunoprecipitated with anti-FLAG M2 antibody and immunoblotted
(IB) for E2 (II-1). (B) Ubiquitin-binding-defective Tax1BP1 mutants increase the level of BPV1 E2 protein. C33A cells were transfected with
expression vectors for BPV1 E2 and FLAG-tagged wild-type Tax1BP1 (WT), UBZ1, UBZ2, UBZ*, or control vector. Cell extracts were resolved
on SDS-PAGE and immunoblotted for FLAG-Tax1BP1 (M2), E2 (B201), or -actin. (C) in vivo ubiquitination assay. C33A cells were transfected
with expression constructs for BPV1 E2, FLAG-tagged full-length Tax1BP1, and HA-tagged ubiquitin. Forty hours posttransfection, the protea-
some inhibitor MG132 dissolved in DMSO was added to the cells for 6 h at a final concentration of 10 M. Cell extracts were immunoprecipitated
with anti-E2 antibody (II-1) or rabbit IgG and immunoblotted for HA-ubiquitin (12CA5), FLAG-Tax1BP1 (M2), or E2 (B201).
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whether the observed coactivator function of Tax1BP1 could
simply be due to an increased E2 level. Though this is possible,
the elevated E2 cannot be the only contributing factor because
TXBP-Cter also stabilizes E2 but did not enhance E2-de-
pendent transcription (Fig. 3D). These results distinguish
the function of Tax1BP1 in transcriptional coactivation from
that of E2 stabilization. It is possible that the initial com-
plexes of Tax1BP1 with E2 and p300 at the viral LCR tran-
siently stimulate E2 transcriptional activity. E2 is then either
modified or targeted to a different subcellular compartment,
where it is rendered transcriptionally inactive. Further stud-
ies are needed to elucidate the functional link between these
two properties of Tax1BP1.
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